<?xml version="1.0" encoding="UTF-8"?>
<p>Remdesivir (RDV, GS‐5734) is an adenosine analogue that has completed the clinical trial phase III for the purpose of viral infection control caused by the Ebola virus. The remdesivir is entered to the phase III clinical trials in Asian countries to assess the use of anti‐viral drug candidate for the potential treatment of SARS‐CoV‐2 by Gilead Sciences. All reported potential drug candidates in clinical trials and their status are presented in Table 
 <xref rid="tbed13734-tbl-0002" ref-type="table">2</xref>. Moreover, multiple parallel attempts are in progress to develop SARS‐CoV‐2 vaccine. At the time of writing the article, 128 vaccine candidates are in preclinical phases and 16 candidates are in clinical phases (Table 
 <xref rid="tbed13734-tbl-0003" ref-type="table">3</xref>).
</p>
